Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC596 and Radiotherapy in Pediatric Newly Diagnosed DIPG and HGG
NCT03605550Phase 1Active, not recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Aug 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unesbulin in diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG), sponsored by Nationwide Children's Hospital. Primary endpoints: Maximum Tolerated Dose and Recommended Phase II Dose, Treatment-related adverse events and 3 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
unesbulin
03
Conditions
diffuse intrinsic pontine glioma (DIPG)high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03605550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605550.